EyePoint EYPT
NASDAQ EYPT
$0.36 +0.00 (+0.53%)
At close: Nov 9, 2026 · 4:00 PM EST

EyePoint (EYPT) Gains from Sales and Divestitures (2013 - 2014)

Updated

Analysis

EyePoint (EYPT) Gains from Sales and Divestitures (2013 - 2014) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,261.99 Bn 1,235.61 Bn 20.46 Bn
2 Johnson & Johnson 678.93 Bn 598.79 Bn 17.30 Bn
3 AbbVie 518.29 Bn 486.30 Bn 13.12 Bn
4 Merck 365.98 Bn 328.92 Bn 13.19 Bn
5 Novartis Ag 316.85 Bn 290.09 Bn -
6 Astrazeneca 293.40 Bn 267.29 Bn 13.26 Bn
7 Amgen 251.78 Bn 203.43 Bn 7.58 Bn
8 Gilead Sciences 210.61 Bn 185.71 Bn 6.73 Bn
9 Pfizer 166.87 Bn 114.23 Bn 12.56 Bn
10 EyePoint 31.41 Mn -881.72 Mn 507,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2014 2,000.00
Mar 31, 2014 4,000.00
Dec 31, 2013 72,000.00
API Access

EyePoint Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=EYPT&period=max&api_key=YOUR_API_KEY